{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-071093","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.631189+00:00","generated_at":"2026-06-07T11:13:10.326883+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Lyra Therapeutics amends bylaws to align with universal proxy rules and update stockholder meeting procedures","bullets":["Board approved amended bylaws effective Dec 14, 2023, addressing SEC universal proxy Rule 14a-19.","New rules require additional disclosures from stockholders nominating directors or proposing business.","Stockholders soliciting proxies must use a non-white proxy card; obsolete provisions deleted.","Changes are procedural and governance-related; no financial impact disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-071093","json":"https://secwatch.observer/filing/0000950170-23-071093.json","markdown":"https://secwatch.observer/filing/0000950170-23-071093.md","text":"https://secwatch.observer/filing/0000950170-23-071093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/0000950170-23-071093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/lyra-20231214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:13:10.326883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a66fe3c16237daaba4de1bec8a858d856d1f86d2","claim":"Lyra Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination and proposal procedures, require a non-white proxy card for soliciting stockholders, and delete obsolete provisions with technical changes (effective 2023-12-14).","evidence_excerpt":"On December 14, 2023, the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/0000950170-23-071093-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}